Skip to main content
Signal8
Launch Terminal

LISATA THERAPEUTICS, INC. (LSTA)

Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Lisata Therapeutics, Inc. logo

Lisata Therapeutics, Inc.

NASDAQ:LSTAHealthcare
+0.99%$1.02
AH$1.02+0.00%vs close
Mkt Cap$11.02M
Float7.43M
O/S10.8M
Vol
$ Vol
RVOL
Inst Own11.1%
Earnings
Dilution
Lisata Therapeutics, Inc. logoNASDAQ:LSTA$1.02+0.99%
Phase Distribution
17 lead-sponsored trials·0 active·11 completed
Phase 14
Phase 1/22
Phase 28
Phase 32
Not applicable1
Status Overview
Completed11
Stopped6

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 3
    Completed

    Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina

    Auto-CD34+ cells, Placebo: Diluent used to suspend Auto-CD34+ cells

    Chronic Myocardial Ischemia, Refractory Angina Pectoris +1

    Enrollment
    291
    Start
    Apr 2012
    Primary Completion
    Nov 2015
    Completion
    Nov 2015
    NCT01508910
  • Phase 3
    Terminated

    Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma

    Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC), Autologous PBMCs in GM-CSF (MC)

    Stage IV Melanoma, Stage III Melanoma

    Enrollment
    4
    Start
    Oct 2014
    Primary Completion
    Jan 2016
    Completion
    Jan 2016
    NCT01875653
  • Phase 2
    Completed

    ACT34-CMI -- Adult Autologous CD34+ Cells

    CLBS14 (low-dose), CLBS14 (high-dose)

    Myocardial Ischemia

    Enrollment
    321
    Start
    Apr 2006
    Primary Completion
    Mar 2008
    Completion
    Mar 2009
    NCT00300053
  • Phase 2
    Withdrawn

    Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery

    lymphokine-activated killer cells, polifeprosan 20 with carmustine implant

    Brain and Central Nervous System Tumors

    Enrollment
    0
    Start
    Nov 2008
    Primary Completion
    Apr 2011
    Completion
    Sep 2011
    NCT00814593
  • Phase 2
    Completed

    NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction

    NBS10

    ST Segment Elevation Myocardial Infarction

    Enrollment
    195
    Start
    Dec 2011
    Primary Completion
    Jun 2014
    Completion
    Apr 2016
    NCT01495364
  • Phase 2
    Completed

    Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI)

    CLBS12, SOC

    Critical Limb Ischemia, Buerger Disease +2

    Enrollment
    33
    Start
    Nov 2017
    Primary Completion
    May 2022
    Completion
    May 2022
    NCT02501018
  • Phase 2
    Completed

    Safety and Efficacy of CLBS03 in Adolescents With Recent Onset Type 1 Diabetes (The Sanford Project T-Rex Study)

    CLBS03 Low Dose, CLBS03 High Dose

    Diabetes Mellitus

    Enrollment
    113
    Start
    Feb 2016
    Primary Completion
    Mar 2019
    Completion
    Jan 2020
    NCT02691247
  • Phase 2
    Completed

    Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease

    CLBS16

    Coronary Microvascular Dysfunction

    Enrollment
    20
    Start
    Apr 2018
    Primary Completion
    Dec 2019
    Completion
    May 2020
    NCT03508609
  • Phase 2
    Terminated

    A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction

    CLBS16, Placebo

    Coronary Microvascular Dysfunction, Coronary Microvascular Disease +1

    Enrollment
    34
    Start
    Oct 2020
    Primary Completion
    Sep 2022
    Completion
    Sep 2022
    NCT04614467
  • Phase 2
    Completed

    A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors

    certepetide, Durvalumab

    Cholangiocarcinoma, Gallbladder Cancer +6

    Enrollment
    66
    Start
    May 2023
    Primary Completion
    Apr 2026
    Completion
    Apr 2026
    NCT05712356
  • Phase 1/2
    Completed

    Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma

    therapeutic autologous dendritic cells

    Melanoma (Skin)

    Enrollment
    56
    Start
    Jul 2000
    Primary Completion
    Apr 2011
    Completion
    Apr 2011
    NCT00012064
  • Phase 1/2
    Withdrawn

    Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC

    certepetide, nab-paclitaxel

    Pancreas Cancer, Pancreatic Carcinoma +6

    Enrollment
    0
    Start
    Jan 2030est.
    Primary Completion
    Jan 2035est.
    Completion
    Jan 2040est.
    NCT06592664
  • Phase 1
    Terminated

    Vaccine Therapy in Treating Patients With Kidney Cancer

    Biological/Vaccine: therapeutic autologous dendritic cells.

    Kidney Cancer

    Enrollment
    9
    Start
    Nov 2001
    Primary Completion
    Dec 2009
    Completion
    Dec 2009
    NCT00014131
  • Phase 1
    Completed

    CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer

    CEND-1, Nab-paclitaxel

    Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma

    Enrollment
    30
    Start
    Jul 2018
    Primary Completion
    Jun 2020
    Completion
    Jun 2020
    NCT03517176
  • Phase 1
    Withdrawn

    CLBS119 for Repair of COVID-19 Induced Pulmonary Damage

    CLBS119

    Covid-19

    Enrollment
    0
    Start
    Oct 2020
    Primary Completion
    May 2021est.
    Completion
    May 2021est.
    NCT04522817
  • Phase 1
    Completed

    CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM)

    CLBS201

    Chronic Kidney Diseases

    Enrollment
    6
    Start
    Jan 2022
    Primary Completion
    Jan 2023
    Completion
    Jan 2023
    NCT04990427
  • Observational
    Completed

    ACT34-CMI -- Adult Autologous CD34+ Stem Cells (Follow-Up Study)

    -

    Myocardial Ischemia

    Enrollment
    150
    Start
    Oct 2007
    Primary Completion
    Apr 2010
    Completion
    Jun 2010
    NCT00545610
Search ClinicalTrials.gov for “Lisata Therapeutics”